California State Teachers Retirement System Purchases 3,409 Shares of Glaukos Co. (NYSE:GKOS)

California State Teachers Retirement System grew its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 7.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,949 shares of the medical instruments supplier's stock after buying an additional 3,409 shares during the period. California State Teachers Retirement System owned 0.09% of Glaukos worth $7,639,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. IFP Advisors Inc bought a new stake in Glaukos in the fourth quarter worth approximately $43,000. Asset Planning Inc bought a new stake in shares of Glaukos in the 4th quarter valued at $90,000. CoreCap Advisors LLC increased its stake in shares of Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after acquiring an additional 200 shares in the last quarter. Picton Mahoney Asset Management acquired a new position in shares of Glaukos during the 4th quarter valued at $125,000. Finally, SBI Securities Co. Ltd. bought a new position in Glaukos during the fourth quarter worth $153,000. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 5.80% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GKOS shares. Needham & Company LLC dropped their price objective on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Morgan Stanley dropped their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Mizuho reduced their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Stifel Nicolaus lowered their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Finally, Truist Financial reiterated a "buy" rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Stock Down 0.2%

GKOS stock traded down $0.23 during trading on Tuesday, reaching $94.56. The stock had a trading volume of 740,396 shares, compared to its average volume of 925,066. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.40 billion, a price-to-earnings ratio of -32.95 and a beta of 0.83. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71. The company's 50 day moving average is $92.44 and its two-hundred day moving average is $122.60.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The company had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos's revenue was up 24.6% on a year-over-year basis. During the same period last year, the business posted ($0.70) earnings per share. Equities research analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.